PGGM Investments Raises Stake in IQVIA Holdings Inc. $IQV

PGGM Investments raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 22.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 243,486 shares of the medical research company’s stock after buying an additional 44,788 shares during the quarter. PGGM Investments owned approximately 0.14% of IQVIA worth $54,884,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA in the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. raised its position in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of IQVIA during the 4th quarter valued at approximately $27,000. Westside Investment Management Inc. raised its position in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the period. Finally, Measured Wealth Private Client Group LLC purchased a new position in IQVIA in the third quarter worth approximately $30,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

NYSE IQV opened at $168.28 on Tuesday. The stock has a fifty day simple moving average of $169.83 and a 200-day simple moving average of $197.14. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market cap of $28.09 billion, a PE ratio of 20.85, a P/E/G ratio of 1.61 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the company earned $2.70 EPS. IQVIA’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has initiated a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

Several brokerages recently weighed in on IQV. Truist Financial lowered their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. JPMorgan Chase & Co. lowered their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Citigroup lowered their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Jefferies Financial Group lowered their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, Royal Bank Of Canada began coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.